Evidence map›Paper›PMID 34605153›Full record

ArticleHIV medicine2022

Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection.

F Hovaguimian, E Martin, M Reinacher, M Rasi, A J Schmidt, E Bernasconi, E Boffi El Amari, D L Braun, A Calmy, K Darling and 18 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03893188 (A Multicenter, Observational Cohort to Study the Characteristics of Individuals Asking for Pre-exposure Prophylaxis), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03893188 recruitingnot on this map

A Multicenter, Observational Cohort to Study the Characteristics of Individuals Asking for Pre-exposure Prophylaxis (PrEP) and the Incidence of HIV and Other Sexually Transmitted Infections: 'The SwissPrEPared Study'

TypeobservationalSponsorUniversity of ZurichRan2019 to 2030Enrolled3,000ConditionsHIV Preexposure Prophylaxis
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

F HovaguimianDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-4181-2948
E MartinDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
M ReinacherDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
M RasiDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
A J SchmidtDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
E BernasconiDivision of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.
E Boffi El AmariInfectious Diseases and Internal Medicine Private Practice, Geneva, Switzerland.
D L BraunDivision of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, Switzerland.
A CalmyLaboratory of Virology and Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
K DarlingInfectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1449-3873
V ChristinetCheckpoint Vaud, Lausanne, Switzerland.
C DepmeierPrivate practice Kalkbreite, Zurich, Switzerland.
C HauserDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
S LäuchliDermatologic Centre Zurich, Zurich, Switzerland.
J NotterDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
M StoeckleDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
B SurialDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
P VernazzaDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
P BruggmannArud Centre for Addiction Medicine, Zurich, Switzerland.
P TarrKantonsspital Baselland, University of Basel, Basel, Switzerland.
D HaerryPositive Council, Zurich, Switzerland.
R BizeDepartment of Epidemiology and Health Systems, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
N LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
A LehnerSwiss AIDS Federation, Zurich, Switzerland.
J BöniInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
R D KouyosDivision of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, Switzerland.
J S FehrDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
B HampelDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of the study was to assess the feasibility of a national pre-exposure prophylaxis (PrEP) programme using smartphone-compatible data collection.

methodsThis was a multicentre cohort study (NCT03893188) enrolling individuals interested in PrEP in Switzerland. All centres participate in the SwissPrEPared programme, which uses smartphone-compatible data collection. Feasibility was assessed after centres had enrolled at least one participant. Participants were HIV-negative individuals presenting for PrEP counselling. Outcomes were participation (number enrolled/number eligible), enrolment rates (number enrolled per month), retention at first follow-up (number with first follow-up/number enrolled), and uptake (proportion attending first visit as scheduled). Participant characteristics were compared between those retained after baseline assessment and those who dropped out.

resultsBetween April 2019 and January 2020, 987 individuals were assessed for eligibility, of whom 969 were enrolled (participation: 98.2%). The median enrolment rate was 86 per month [interquartile range (IQR) 52-137]. Retention at first follow-up and uptake were both 80.7% (782/969 and 532/659, respectively). At enrolment, the median age was 40 (IQR 33-47) years, 95% were men who have sex with men, 47% had a university degree, and 75.5% were already taking PrEP. Most reported multiple casual partners (89.2%), previous sexually transmitted infections (74%) and sexualized drug use (73.1%). At baseline, 25.5% tested positive for either syphilis, gonorrhoea or chlamydia. Participants who dropped out were at lower risk of HIV infection than those retained after baseline assessment.

conclusionsIn a national PrEP programme using smartphone-compatible data collection, participation, retention and uptake were high. Participants retained after baseline assessment were at considerable risk of HIV infection. Younger, less educated individuals were underrepresented in the SwissPrEPared cohort.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesAdultCohort StudiesData CollectionHomosexuality, MaleHumansMaleSmartphoneAnti-HIV Agentscohort studyHIVpre-exposure prophylaxisprevention programme

Identifiers

PMID34605153
PMCPMC9292805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.